Effects and Mechanisms of Transcranial Direct Current Stimulation Combined With Dialectical Behavior Therapy Skills Training in Adults With Attention-Deficit/Hyperactivity Disorder
Effects and Mechanisms of Transcranial Direct Current Stimulation Combined with Dialectical Behavior Therapy Skills Training in Adults with Attention-Deficit/Hyperactivity Disorder
Abstract Adult attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that frequently persists into adulthood and is associated with substantial impairments in academic, occupational, and social functioning. Although pharmacological treatment remains the primary intervention, some adults with ADHD show limited response to medication or experience adverse effects, highlighting the need for effective non-pharmacological or combined treatment approaches. Dialectical Behavior Therapy Skills Training (DBT-ST), which emphasizes emotion regulation, impulse control, mindfulness, and behavioral organization, has shown potential in the treatment of adult ADHD. However, its therapeutic efficacy may vary across individuals, and strategies to enhance treatment outcomes still require further investigation. In parallel, transcranial direct current stimulation (tDCS), a safe and non-invasive neuromodulation technique, has attracted increasing attention as an adjunctive intervention in psychiatric disorders. Existing studies suggest that combining tDCS with psychotherapy may optimize treatment effects by modulating neural networks related to cognitive control and emotional regulation. Nevertheless, evidence for such combined interventions in adult ADHD remains limited, particularly with respect to rigorous randomized controlled designs and mechanism-based neuroimaging validation.
The present study aims to investigate the efficacy and potential mechanisms of tDCS combined with DBT-ST in adults with ADHD. A randomized, double-blind, sham-controlled design will be adopted. Sixty eligible adult participants with ADHD will be randomly assigned to either an active tDCS group or a sham stimulation group, with both groups receiving weekly DBT-ST for ten consecutive weeks. tDCS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) with 2 mA current for 20 minutes, prior to each group therapy session. Clinical symptoms, functional outcomes, and cognitive performance will be assessed at baseline, post-intervention, and one-month follow-up using standardized self-report measures and behavioral tasks. In addition, resting-state functional magnetic resonance imaging (rs-fMRI) will be conducted before and after the intervention to examine changes in functional connectivity within prefrontal regulatory networks.
This study is expected to clarify whether tDCS can enhance the therapeutic effects of DBT-ST on core ADHD symptoms and related functional outcomes, and whether such effects are associated with improvements in executive function, emotion regulation, and alterations in DLPFC-related resting-state functional connectivity. By integrating clinical, behavioral, and neuroimaging measures, the study seeks to provide preliminary evidence for a novel non-pharmacological combined intervention for adult ADHD and to further elucidate its underlying neural mechanisms.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Chun Wang, PhD
- 电话号码:15850566376
- 邮箱:wang_chun@nju.edu.cn
研究联系人备份
- 姓名:Yu Xin Luo
- 电话号码:18982002847
- 邮箱:felicia18982002847@163.com
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 招聘中
- Nanjing Brain Hospital
-
接触:
- Chun Wang, PhD
- 电话号码:15850566376
- 邮箱:wang_chun@nju.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Meet the diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Diagnosis confirmed using the Chinese version of the Diagnostic Interview for ADHD in Adults (DIVA-5).
- Aged between 18 and 55 years.
- Right-handed.
- Voluntary participation with provision of written informed consent.
Exclusion Criteria:
- Presence of neurological disorders or other psychiatric disorders.
- Severe physical illness.
- Receipt of electroconvulsive therapy (ECT) or other physical treatments within 6 months prior to enrollment.
- Planned changes in ADHD-related medication before the final follow-up assessment.
- Contraindications to tDCS (e.g., intracranial metal or electronic implants, skull plates, or other cranial implants).
- Pregnancy or breastfeeding.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active tDCS + DBT-ST
Participants receive active transcranial direct current stimulation (tDCS) over the bilateral dorsolateral prefrontal cortex combined with dialectical behavior therapy skills training (DBT-ST).
|
Transcranial direct current stimulation (tDCS) is administered over the bilateral dorsolateral prefrontal cortex (DLPFC).
In the active condition, a constant current of 2 mA is applied for 20 minutes per session, twice prior to each weekly therapy session, for 10 weeks.
The anodal electrode is placed over the left DLPFC (F3) and the cathodal electrode over the right DLPFC (F4).
In the sham condition, the current is ramped up and down briefly to mimic the sensation of stimulation without delivering an effective dose.
其他名称:
|
|
假比较器:Sham tDCS + DBT-ST
Participants receive sham transcranial direct current stimulation (tDCS) combined with dialectical behavior therapy skills training (DBT-ST).
|
Transcranial direct current stimulation (tDCS) is administered over the bilateral dorsolateral prefrontal cortex (DLPFC).
In the active condition, a constant current of 2 mA is applied for 20 minutes per session, twice prior to each weekly therapy session, for 10 weeks.
The anodal electrode is placed over the left DLPFC (F3) and the cathodal electrode over the right DLPFC (F4).
In the sham condition, the current is ramped up and down briefly to mimic the sensation of stimulation without delivering an effective dose.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in ADHD symptoms as measured by the Adult ADHD Self-Report Scale (ASRS)
大体时间:Baseline to 10 weeks (post-intervention)
|
ADHD symptom severity will be assessed using the Adult ADHD Self-Report Scale (ASRS).
The ASRS is a self-administered questionnaire consisting of 18 items.
The total score ranges from 0 to 72, with higher scores indicating more severe ADHD symptoms.
The primary outcome is the change in ASRS total score from baseline to post-intervention (10 weeks).
|
Baseline to 10 weeks (post-intervention)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in executive function performance as measured by the Stop-Signal Task (SST)
大体时间:Baseline to 10 weeks
|
Executive function will be assessed using the Stop-Signal Task (SST).
The outcome measure is the stop-signal reaction time (SSRT), reported in milliseconds.
The change in SSRT from baseline to post-intervention will be analyzed.
|
Baseline to 10 weeks
|
|
Change in emotion regulation ability as measured by the Difficulties in Emotion Regulation Scale (DERS)
大体时间:Baseline to 10 weeks (post-intervention)
|
Emotion regulation will be assessed using the Difficulties in Emotion Regulation Scale (DERS).
The DERS is a 36-item self-report questionnaire.
The total score ranges from 36 to 180, with higher scores indicating greater difficulties in emotion regulation.
The change in DERS total score from baseline to post-intervention will be evaluated.
|
Baseline to 10 weeks (post-intervention)
|
|
Change in anxiety symptoms as measured by the Generalized Anxiety Disorder-7 (GAD-7)
大体时间:Baseline to 10 weeks (post-intervention)
|
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale.
The GAD-7 is a 7-item self-report questionnaire.
The total score ranges from 0 to 21, with higher scores indicating more severe anxiety.
The change in GAD-7 total score from baseline to post-intervention will be evaluated.
|
Baseline to 10 weeks (post-intervention)
|
|
Change in resting-state functional connectivity within prefrontal regulatory networks
大体时间:Baseline to 10 weeks (post-intervention)
|
Resting-state functional connectivity will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI).
The outcome measure is the strength of functional connectivity within prefrontal regulatory networks, focusing on the dorsolateral prefrontal cortex (DLPFC), and is expressed as Fisher's Z-transformed correlation coefficient.
The change in connectivity from baseline to post-intervention will be analyzed.
|
Baseline to 10 weeks (post-intervention)
|
|
Maintenance of treatment effects at 1-month follow-up
大体时间:1-month follow-up
|
Maintenance of treatment effects will be evaluated by reassessing the following clinical and cognitive outcomes at 1-month follow-up and comparing them with baseline values: ASRS total score (range 0-72, higher = worse), SST stop-signal reaction time (milliseconds), N-back d-prime (unitless), DERS total score (36-180, higher = worse), GAD-7 total score (0-21, higher = worse), PHQ-9 total score (0-27, higher = worse), and rs-fMRI DLPFC functional connectivity (Fisher's Z).
Each of these measurements will be analyzed as a separate maintenance endpoint, using the same units of measure as defined in the respective outcomes above.
|
1-month follow-up
|
|
Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
大体时间:Baseline to 10 weeks (post-intervention)
|
Depressive symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a 9-item self-report questionnaire.
The total score ranges from 0 to 27, with higher scores indicating more severe depression.
The change in PHQ-9 total score from baseline to post-intervention will be evaluated.
|
Baseline to 10 weeks (post-intervention)
|
合作者和调查者
调查人员
- 首席研究员:Chun Wang, PhD、Nanjing Brain Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2026-KY022-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.